Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical said that its subsidiary Jinzhou Avanc Pharmaceutical has had its drug registration application for Moxetomidate Hydrochloride Injection accepted by China’s National Medical Products Administration. The class 1 chemical medicine is intended as an intravenous general anesthetic for induction and maintenance of anesthesia during short surgical procedures.
The company noted that the molecule, developed via structural modification of an imidazole-class compound, was included in China’s National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014. Fosun Pharma’s group-wide investment in the project has reached about RMB189 million as of January 2026, underscoring its push into innovative anesthesia therapies and its broader R&D-driven growth strategy.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group active in pharmaceuticals, medical services and related health industries. Through subsidiaries such as Jinzhou Avanc Pharmaceutical, it focuses on the research, development and commercialization of innovative drugs for both domestic and international markets.
Average Trading Volume: 3,805,318
Technical Sentiment Signal: Buy
Current Market Cap: HK$76.87B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.